XENE Xenon Pharmaceuticals Forecast, Technical & Fundamental Analysis
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders... Show more
XENE is expected to report earnings to fall 1.71% to -114 cents per share on August 12
Q2'26
Est.
$-1.15
Q1'26
Beat
by $0.01
Q4'25
Missed
by $0.12
Q3'25
Est.
$-1.15
Q2'25
Beat
by $2.06
The last earnings report on May 07 showed earnings per share of -116 cents, beating the estimate of -117 cents. With 733.02K shares outstanding, the current market capitalization sits at 5.30B.
A.I. Advisor
published General Information
General Information
a provider of drug discovery and development services
A.I.dvisor indicates that over the last year, XENE has been loosely correlated with RLMD. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then RLMD could also see price increases.
XENE sees its Stochastic Oscillator ascends from oversold territory
On June 15, 2026, the Stochastic Oscillator for XENE moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on XENE as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for XENE just turned positive on June 17, 2026. Looking at past instances where XENE's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XENE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
XENE broke above its upper Bollinger Band on June 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XENE entered a downward trend on June 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XENE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.959) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). XENE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (588.235) is also within normal values, averaging (367.026).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
